Latest News

A selection of recent news and views from Catapult Ventures follows...

Monument Therapeutics announces the start of its first clinical study for novel treatment for neuroinflammation

Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been...

Oxford BioTherapeutics announces research collaboration with ImmunoGen to develop novel Antibody-Drug Conjugates

Companies to research Antibody-Drug Conjugates (ADC) to address cancers of high unmet need  Collaboration to utilize ImmunoGen’s ADC linker-payload technology directed to targets identified by OBT Each company may select a n...

Proveca enters an exclusive agreement with Mawdsley Brooks Brazil

Proveca has entered an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil. Under the terms of the agreement, Mawdsley Brooks Brazil w...

Rinicare’s SAFE falls reduction technology granted new UK patent

SAFE has been designed to reduce the burden on overstretched clinicians and care home staff by alerting them to pending falls events. A recently published white paper projected that falls amongst older people will increase by 3.9% a year mean...

Trial to assess Acute Kidney Injury risk prediction technology starts at MFT

A pioneering clinical trial of new technology to predict the risk of patients developing Acute Kidney Injury (AKI) has begun at Manchester University NHS Foundation Trust (MFT). The STABILITY UO (Urine Output) clinical risk prediction te...

From our portfolio

Biofortuna Limited


Biofortuna is a leading developer of HLA diagnostic test kits for the organ transplantation, bloo...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200